Incyte
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 2.5K
- Market Cap
- $12.6B
- Introduction
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 105
- Registration Number
- NCT04272034
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇫🇮Turku University Hospital, Turku, Finland
🇳🇴Haukeland University Hospital, Bergen, Norway
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
- First Posted Date
- 2020-01-27
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 182
- Registration Number
- NCT04242199
- Locations
- 🇺🇸
Upmc Cancercenter, Pittsburgh, Pennsylvania, United States
🇦🇺Chris Obrien Lifehouse, Camperdown, New South Wales, Australia
🇺🇸Md Anderson Cancer Center, Houston, Texas, United States
Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer
- First Posted Date
- 2019-12-19
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 583
- Registration Number
- NCT04205812
- Locations
- 🇹🇷
Trakya Universitesi Tip Fakultesi, Edirne, Turkey
🇿🇦Wits Clinical Research, Johannesburg, South Africa
🇺🇦Kherson Regional Oncologic Dispensary, Kherson, Ukraine
INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301)
- First Posted Date
- 2019-12-18
- Last Posted Date
- 2020-06-09
- Lead Sponsor
- Incyte Corporation
- Registration Number
- NCT04203511
A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy
- Conditions
- Interventions
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 112
- Registration Number
- NCT04071366
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)
- First Posted Date
- 2019-08-15
- Last Posted Date
- 2022-09-21
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 344
- Registration Number
- NCT04057573
- Locations
- 🇺🇸
Uci Beckman Laser Institute and Medical Clinic, Irvine, California, United States
🇺🇸UCI Health Beckman Laser Institute and Medical Center, Irvine, California, United States
🇺🇸Vitiligo & Pigmentation Institute of Southern California, Los Angeles, California, United States
Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)
- First Posted Date
- 2019-08-09
- Last Posted Date
- 2022-09-21
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 330
- Registration Number
- NCT04052425
- Locations
- 🇺🇸
Suny Downstate Medical Center, Brooklyn, New York, United States
🇺🇸First Oc Dermatology, Fountain Valley, California, United States
🇺🇸Marvel Clinical Research Llc, Huntington Beach, California, United States
Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)
- Conditions
- Interventions
- First Posted Date
- 2019-07-01
- Last Posted Date
- 2022-05-26
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 7
- Registration Number
- NCT04003610
- Locations
- 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States
🇺🇸The University of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸Mount Sinai School of Medicine, New York, New York, United States
Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208)
- Conditions
- Interventions
- First Posted Date
- 2019-07-01
- Last Posted Date
- 2022-05-10
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 1
- Registration Number
- NCT04003623
- Locations
- 🇺🇸
Hawaii Cancer Care, Honolulu, Hawaii, United States
🇺🇸FMH James M Stockman Cancer Institute, Frederick, Maryland, United States
🇺🇸Ocala Oncology Center, Ocala, Florida, United States
Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation
- First Posted Date
- 2019-06-07
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 23
- Registration Number
- NCT03978637
- Locations
- 🇺🇸
Brigham and Women'S Faulkner Hospitals Inc, Boston, Massachusetts, United States
🇺🇸Temple University Department of Thoracic Medicine and Surgery, Philadelphia, Pennsylvania, United States
🇧🇪Universitaire Ziekenhuis Leuven - Gasthuisberg, Leuven, Belgium